Figure 2.
Levels of IgG antibodies against SARS-CoV-2 RBD (Omicron BA.4/5) protein in solid carcinoma patients and healthy controls. This figure compares the anti-RBD-IgG (BA.4/5) titers in SARS-CoV-2 infected and uninfected individuals for both solid carcinoma patients and healthy controls. The anti-RBD-IgG titers are presented as absorbance (OD450-630); the values were read at wavelengths of 450 nm and 630 nm. Statistical analyses were conducted using the Kruskal–Wallis test. ns, not significant; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001.